CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice

In this study, the value of the serum tumor markers carcinoembryonic antigen (CEA), CA 19‐9, and CA 125 was assessed in the differential diagnosis of benign and malignant pancreatic diseases with and without obstructive jaundice.

[1]  R. Bold,et al.  Utility of tumor markers in determining resectability of pancreatic cancer. , 2003, Archives of surgery.

[2]  R. Klapdor,et al.  Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease. , 2000, Anticancer research.

[3]  R. Edwards,et al.  Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  A. van Dalen,et al.  Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis , 2000, Cancer.

[5]  W. Schlosser,et al.  Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms , 1997, Journal of Gastrointestinal Surgery.

[6]  Y. Miyauchi,et al.  Carcinoembryonic antigen (CEA) and CEA-related substances in the bile of patients with biliary diseases. , 1994, American journal of surgery.

[7]  H. Joller,et al.  CA 242 is a new tumor marker for pancreatic cancer , 1993, Cancer.

[8]  N. Habib,et al.  Clinical evaluation of combined use of CEA, CA19-9 and CA50 in the serum of patients with pancreatic carcinoma. , 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[9]  K. Endo,et al.  Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. , 1990, The American journal of gastroenterology.

[10]  F. Safi,et al.  Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. , 1989, Hepato-gastroenterology.

[11]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[12]  H. Aste,et al.  CA 19‐9 and CA 50 in Benign and malignant pancreatic and biliary diseases , 1988, Cancer.

[13]  H. Egami,et al.  Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. , 1987, Gut.

[14]  J. Bidart,et al.  Elevation of CA 125 in patients with benign and malignant ascites , 1987, Cancer.

[15]  C. Haglund.  Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. , 1986, British Journal of Cancer.

[16]  A. Piccoli,et al.  CA 19‐9 and carcinoembryonic antigen in pancreatic cancer diagnosis , 1986, Cancer.

[17]  M. Büchler,et al.  CA 19‐9 and pancreatic adenocarcinoma , 1986, Cancer.

[18]  C. Haglund,et al.  Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. , 1986, British Journal of Cancer.

[19]  S. Kurtzman,et al.  Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. , 1986, Gastroenterology.

[20]  E. Martin,et al.  Factors controlling the circulating CEA levels in pancreatic cancer: Some clinical correlations , 1981, Cancer.

[21]  J. Barkin,et al.  Circulating carcinoembryonic antigen in pancreatic carcinoma , 1978, Cancer.

[22]  N. Zamcheck,et al.  Elevated carcinoembryonic antigen levels and biliary tract obstruction. , 1975, JAMA.